$XLO
Xilio Therapeutics Inc

2022 Q1 Form 10-Q Financial Statement

#000155837022008441 Filed on May 12, 2022

View on sec.gov

Income Statement

Concept 2022 Q1 2021 Q1
Revenue $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $6.304M $4.899M
YoY Change 28.68% 116.58%
% of Gross Profit
Research & Development $14.92M $11.62M
YoY Change 28.39% 106.19%
% of Gross Profit
Depreciation & Amortization $440.0K $350.0K
YoY Change 25.71% 167.18%
% of Gross Profit
Operating Expenses $21.22M $16.52M
YoY Change 28.47% 109.17%
Operating Profit -$21.22M -$16.52M
YoY Change 28.47%
Interest Expense -$200.0K
YoY Change
% of Operating Profit
Other Income/Expense, Net -$129.0K -$147.0K
YoY Change -12.24% -33.18%
Pretax Income -$21.35M -$16.67M
YoY Change 28.12% 105.31%
Income Tax $0.00 $0.00
% Of Pretax Income
Net Earnings -$21.35M -$16.67M
YoY Change 28.12% 105.31%
Net Earnings / Revenue
Basic Earnings Per Share -$0.78 -$23.53
Diluted Earnings Per Share -$0.78 -$23.53
COMMON SHARES
Basic Shares Outstanding 27.37M 708.3K
Diluted Shares Outstanding

Balance Sheet

Concept 2022 Q1 2021 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $177.0M $141.2M
YoY Change 25.31%
Cash & Equivalents $177.0M $141.2M
Short-Term Investments
Other Short-Term Assets $4.128M $1.400M
YoY Change 194.86%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $181.1M $142.6M
YoY Change 26.97%
LONG-TERM ASSETS
Property, Plant & Equipment $7.468M $13.70M
YoY Change -45.49%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $359.0K $2.023M
YoY Change -82.25%
Total Long-Term Assets $15.27M $15.72M
YoY Change -2.91%
TOTAL ASSETS
Total Short-Term Assets $181.1M $142.6M
Total Long-Term Assets $15.27M $15.72M
Total Assets $196.4M $158.3M
YoY Change 24.0%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $2.324M $2.608M
YoY Change -10.89%
Accrued Expenses $7.323M $10.27M
YoY Change -28.7%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due $1.667M $3.333M
YoY Change -49.98%
Total Short-Term Liabilities $12.23M $16.29M
YoY Change -24.97%
LONG-TERM LIABILITIES
Long-Term Debt $8.012M $6.448M
YoY Change 24.26%
Other Long-Term Liabilities $100.0K $11.85M
YoY Change -99.16%
Total Long-Term Liabilities $100.0K $18.30M
YoY Change -99.45%
TOTAL LIABILITIES
Total Short-Term Liabilities $12.23M $16.29M
Total Long-Term Liabilities $100.0K $18.30M
Total Liabilities $30.23M $34.59M
YoY Change -12.6%
SHAREHOLDERS EQUITY
Retained Earnings -$182.2M
YoY Change
Common Stock $3.000K
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $166.1M -$99.14M
YoY Change
Total Liabilities & Shareholders Equity $196.4M $158.3M
YoY Change 24.0%

Cashflow Statement

Concept 2022 Q1 2021 Q1
OPERATING ACTIVITIES
Net Income -$21.35M -$16.67M
YoY Change 28.12% 105.31%
Depreciation, Depletion And Amortization $440.0K $350.0K
YoY Change 25.71% 167.18%
Cash From Operating Activities -$20.84M -$22.73M
YoY Change -8.35% 363.3%
INVESTING ACTIVITIES
Capital Expenditures $254.0K $170.0K
YoY Change 49.41% -121.52%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities -$254.0K -$170.0K
YoY Change 49.41% -78.48%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -5.000K 144.9M
YoY Change -100.0% 1353.41%
NET CHANGE
Cash From Operating Activities -20.84M -22.73M
Cash From Investing Activities -254.0K -170.0K
Cash From Financing Activities -5.000K 144.9M
Net Change In Cash -21.09M 122.0M
YoY Change -117.29% 2755.48%
FREE CASH FLOW
Cash From Operating Activities -$20.84M -$22.73M
Capital Expenditures $254.0K $170.0K
Free Cash Flow -$21.09M -$22.90M
YoY Change -7.92% 456.33%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2022Q1 dei Amendment Flag
AmendmentFlag
false
CY2022Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2021Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022Q1 us-gaap Fair Value Liabilities Level2 To Level1 Transfers Amount
FairValueLiabilitiesLevel2ToLevel1TransfersAmount
0
CY2022Q1 us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-185000
CY2021Q1 us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-30000
CY2021Q4 us-gaap Fair Value Liabilities Level2 To Level1 Transfers Amount
FairValueLiabilitiesLevel2ToLevel1TransfersAmount
0
CY2022Q1 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Liability Transfers Into Level3
FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3
0
CY2021 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Liability Transfers Into Level3
FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3
0
CY2022Q1 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Liability Transfers Out Of Level3
FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3
0
CY2021 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Liability Transfers Out Of Level3
FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3
0
CY2021Q4 us-gaap Stockholders Equity Note Stock Split Conversion Ratio1
StockholdersEquityNoteStockSplitConversionRatio1
0.1053
CY2022Q1 dei Document Type
DocumentType
10-Q
CY2021Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
118000
CY2022Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
440000
CY2021Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
350000
CY2022Q1 xlo Noncash Interest Expense
NoncashInterestExpense
53000
CY2021Q1 xlo Noncash Interest Expense
NoncashInterestExpense
38000
CY2022Q1 us-gaap Share Based Compensation
ShareBasedCompensation
2029000
CY2021Q1 us-gaap Share Based Compensation
ShareBasedCompensation
794000
CY2021Q1 xlo Fair Value Adjustments Of Warrants And Derivative Liabilities
FairValueAdjustmentsOfWarrantsAndDerivativeLiabilities
15000
CY2022Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-336000
CY2021Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-153000
CY2022Q1 xlo Increase Decrease In Operating Lease Right Of Use Asset
IncreaseDecreaseInOperatingLeaseRightOfUseAsset
-92000
CY2021Q1 xlo Increase Decrease In Operating Lease Right Of Use Asset
IncreaseDecreaseInOperatingLeaseRightOfUseAsset
-78000
CY2022Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-820000
CY2022Q1 dei Document Period End Date
DocumentPeriodEndDate
2022-03-31
CY2022Q1 dei Document Quarterly Report
DocumentQuarterlyReport
true
CY2022Q1 dei Document Transition Report
DocumentTransitionReport
false
CY2022Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-21353000
CY2021Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-16667000
CY2022Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.78
CY2021Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-23.53
CY2022Q1 us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
27367377
CY2021Q1 us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
708264
CY2022Q1 dei Entity Central Index Key
EntityCentralIndexKey
0001840233
CY2022Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2022Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2022
CY2022Q1 us-gaap Preferred Stock Value
PreferredStockValue
CY2021Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2022Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2021Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
10107000
CY2022Q1 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
100000
CY2022Q1 dei Entity File Number
EntityFileNumber
001-40925
CY2022Q1 dei Entity Registrant Name
EntityRegistrantName
Xilio Therapeutics, Inc.
CY2022Q1 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2022Q1 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
85-1623397
CY2022Q1 dei Entity Address Address Line1
EntityAddressAddressLine1
828 Winter Street
CY2022Q1 dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 300
CY2022Q1 dei Entity Address City Or Town
EntityAddressCityOrTown
Waltham
CY2022Q1 dei Entity Address State Or Province
EntityAddressStateOrProvince
MA
CY2022Q1 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
02451
CY2022Q1 dei City Area Code
CityAreaCode
617
CY2022Q1 dei Local Phone Number
LocalPhoneNumber
430-4680
CY2022Q1 dei Security12b Title
Security12bTitle
Common stock, par value $0.0001 per share
CY2022Q1 dei Trading Symbol
TradingSymbol
XLO
CY2022Q1 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2022Q1 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2022Q1 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2022Q1 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2022Q1 dei Entity Small Business
EntitySmallBusiness
true
CY2022Q1 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
CY2022Q1 dei Entity Ex Transition Period
EntityExTransitionPeriod
false
CY2022Q1 dei Entity Shell Company
EntityShellCompany
false
CY2022Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
27471607
CY2022Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
176959000
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
198053000
CY2022Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
4128000
CY2021Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
4464000
CY2022Q1 us-gaap Assets Current
AssetsCurrent
181087000
CY2021Q4 us-gaap Assets Current
AssetsCurrent
202517000
CY2022Q1 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
1553000
CY2021Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
1553000
CY2022Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
7468000
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
7620000
CY2022Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
5885000
CY2021Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
5977000
CY2022Q1 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
359000
CY2021Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
393000
CY2022Q1 us-gaap Assets
Assets
196352000
CY2021Q4 us-gaap Assets
Assets
218060000
CY2022Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
2324000
CY2021Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
3144000
CY2022Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
7323000
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
8751000
CY2022Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
829000
CY2021Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
801000
CY2022Q1 us-gaap Notes Payable Current
NotesPayableCurrent
1667000
CY2022Q1 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
82000
CY2021Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
82000
CY2022Q1 us-gaap Liabilities Current
LiabilitiesCurrent
12225000
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
-99135000
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
12778000
CY2022Q1 us-gaap Long Term Notes Payable
LongTermNotesPayable
8012000
CY2021Q4 us-gaap Long Term Notes Payable
LongTermNotesPayable
9628000
CY2022Q1 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
9894000
CY2022Q1 us-gaap Liabilities
Liabilities
30231000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
185429000
CY2022Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
16000
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2029000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-21353000
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
166121000
CY2021Q4 us-gaap Liabilities
Liabilities
32631000
CY2022Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2021Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2022Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2021Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2022Q1 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2021Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2022Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2022Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2022Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
27471607
CY2022Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
27376473
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
27468950
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
27358375
CY2022Q1 us-gaap Common Stock Value
CommonStockValue
3000
CY2021Q4 us-gaap Common Stock Value
CommonStockValue
3000
CY2022Q1 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
348357000
CY2021Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
346312000
CY2022Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-182239000
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-160886000
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
166121000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
185429000
CY2022Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
196352000
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
218060000
CY2022Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
14920000
CY2021Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
11621000
CY2022Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
6304000
CY2021Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4899000
CY2022Q1 us-gaap Operating Expenses
OperatingExpenses
21224000
CY2021Q1 us-gaap Operating Expenses
OperatingExpenses
16520000
CY2022Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-21224000
CY2021Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-16520000
CY2022Q1 us-gaap Other Nonoperating Expense
OtherNonoperatingExpense
129000
CY2021Q1 us-gaap Other Nonoperating Expense
OtherNonoperatingExpense
147000
CY2022Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-129000
CY2021Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-147000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-21353000
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-16667000
CY2022Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.78
CY2021Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-23.53
CY2022Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
27367377
CY2021Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
708264
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
-83287000
CY2021Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
25000
CY2021Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
794000
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-16667000
CY2021Q1 us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
-4627000
CY2022Q1 us-gaap Profit Loss
ProfitLoss
-21353000
CY2021Q1 us-gaap Profit Loss
ProfitLoss
-16667000
CY2022Q1 us-gaap Fair Value Liabilities Level1 To Level2 Transfers Amount
FairValueLiabilitiesLevel1ToLevel2TransfersAmount
0
CY2021Q4 us-gaap Fair Value Liabilities Level1 To Level2 Transfers Amount
FairValueLiabilitiesLevel1ToLevel2TransfersAmount
0
CY2021Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-2838000
CY2022Q1 us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
-1427000
CY2021Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
491000
CY2022Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-20835000
CY2021Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-22734000
CY2022Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
254000
CY2021Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
170000
CY2022Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-254000
CY2021Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-170000
CY2022Q1 us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
21000
CY2021Q1 us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
21000
CY2021Q1 us-gaap Proceeds From Issuance Of Convertible Preferred Stock
ProceedsFromIssuanceOfConvertiblePreferredStock
144886000
CY2022Q1 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
16000
CY2021Q1 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
25000
CY2022Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-5000
CY2021Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
144890000
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-21094000
CY2021Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
121986000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
199606000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
20789000
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
178512000
CY2021Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
142775000
CY2022Q1 us-gaap Interest Paid Net
InterestPaidNet
119000
CY2021Q1 us-gaap Interest Paid Net
InterestPaidNet
125000
CY2021Q1 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
249000
CY2021Q1 xlo Deferred Offering Costs Included In Accounts Payable Or Accrued Expenses
DeferredOfferingCostsIncludedInAccountsPayableOrAccruedExpenses
201000
CY2022Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
177000000.0
CY2022Q1 us-gaap Substantial Doubt About Going Concern Within One Year
SubstantialDoubtAboutGoingConcernWithinOneYear
false
CY2022Q1 us-gaap Use Of Estimates
UseOfEstimates
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Use of Estimates</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The preparation of financial statements in accordance with GAAP requires management to make estimates and judgments that may affect the reported amounts of assets and liabilities and related disclosures of contingent assets and liabilities at the date of the financial statements and the related reporting of expenses during the reporting period. Management considers many factors in selecting appropriate financial accounting policies and controls, and in developing the estimates and assumptions that are used in the preparation of these condensed consolidated financial statements. Factors that may affect estimates include expected business and operational changes, sensitivity and volatility associated with the assumptions used in developing estimates, and whether historical trends are expected to be representative of future trends. The estimation process often may yield a range of potentially reasonable estimates of the ultimate future outcomes and management must select an amount that falls within that range of reasonable estimates. Significant estimates of accounting reflected in these condensed consolidated financial statements include, but are not limited to, estimates related to accrued expenses, the valuation of equity-based compensation, including stock options and restricted common stock, the useful life of long-lived assets and income taxes. Actual results could differ from those estimates.</p>
CY2022Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
176959000
CY2021Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
141222000
CY2022Q1 us-gaap Restricted Cash
RestrictedCash
1553000
CY2021Q1 us-gaap Restricted Cash
RestrictedCash
1553000
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
178512000
CY2021Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
142775000
CY2022Q1 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
194000
CY2021Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
321000
CY2022Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
7323000
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
8751000
CY2022Q1 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
10586000
CY2021Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
10332000
CY2022Q1 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
3118000
CY2021Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
2712000
CY2022Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
7468000
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
7620000
CY2021Q1 us-gaap Depreciation
Depreciation
400000
CY2022Q1 us-gaap Depreciation
Depreciation
400000
CY2022Q1 xlo Accrued External Research And Development Current
AccruedExternalResearchAndDevelopmentCurrent
4987000
CY2021Q4 xlo Accrued External Research And Development Current
AccruedExternalResearchAndDevelopmentCurrent
2794000
CY2022Q1 xlo Accrued Personnel Expenses Current
AccruedPersonnelExpensesCurrent
1483000
CY2021Q4 xlo Accrued Personnel Expenses Current
AccruedPersonnelExpensesCurrent
5145000
CY2022Q1 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
659000
CY2019Q3 xlo Lessee Operating Lease Area Leased
LesseeOperatingLeaseAreaLeased
27830
CY2019Q3 us-gaap Lessee Operating Lease Option To Extend
LesseeOperatingLeaseOptionToExtend
true
CY2019Q3 xlo Lessee Operating Lease Extended Lease Term
LesseeOperatingLeaseExtendedLeaseTerm
P5Y
CY2022Q1 us-gaap Letters Of Credit Outstanding Amount
LettersOfCreditOutstandingAmount
1600000
CY2022Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2021Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2022Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2021Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2022Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2022Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2022Q1 xlo Common Stock Capital Shares Reserved For Future Issuance Conversion Of Convertible Preferred Stock Issuable Upon Exercise Of Warrant
CommonStockCapitalSharesReservedForFutureIssuanceConversionOfConvertiblePreferredStockIssuableUponExerciseOfWarrant
2631
CY2021Q4 xlo Common Stock Capital Shares Reserved For Future Issuance Conversion Of Convertible Preferred Stock Issuable Upon Exercise Of Warrant
CommonStockCapitalSharesReservedForFutureIssuanceConversionOfConvertiblePreferredStockIssuableUponExerciseOfWarrant
2631
CY2022Q1 xlo Common Stock Capital Shares Reserved For Future Issuance Exercise Of Outstanding Stock Options
CommonStockCapitalSharesReservedForFutureIssuanceExerciseOfOutstandingStockOptions
4948376
CY2021Q4 xlo Common Stock Capital Shares Reserved For Future Issuance Exercise Of Outstanding Stock Options
CommonStockCapitalSharesReservedForFutureIssuanceExerciseOfOutstandingStockOptions
4088456
CY2022Q1 xlo Common Stock Capital Shares Reserved For Future Issuance Future Stock Based Compensation Awards
CommonStockCapitalSharesReservedForFutureIssuanceFutureStockBasedCompensationAwards
2860745
CY2021Q4 xlo Common Stock Capital Shares Reserved For Future Issuance Future Stock Based Compensation Awards
CommonStockCapitalSharesReservedForFutureIssuanceFutureStockBasedCompensationAwards
2349875
CY2022Q1 xlo Common Stock Capital Shares Reserved For Future Issuance Employee Stock Purchase Plan
CommonStockCapitalSharesReservedForFutureIssuanceEmployeeStockPurchasePlan
566720
CY2021Q4 xlo Common Stock Capital Shares Reserved For Future Issuance Employee Stock Purchase Plan
CommonStockCapitalSharesReservedForFutureIssuanceEmployeeStockPurchasePlan
292031
CY2022Q1 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
8378472
CY2021Q4 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
6732993
CY2022Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2029000
CY2021Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
794000
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
4088456
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
8.59
CY2021 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P9Y1M17D
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
30291000
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
874830
CY2022Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
12.67
CY2022Q1 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
2657
CY2022Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
5.89
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
12253
CY2022Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
13.71
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
4948376
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
9.30
CY2022Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P9Y25D
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
2832000
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
1064255
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
7.09
CY2022Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P8Y3M7D
CY2022Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
1115000
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
4948376
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
9.30
CY2022Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P9Y25D
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
2832000
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
8.83
CY2021Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
4.32
CY2022Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2021Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2022Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
5046141
CY2021Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
21428149

Files In Submission

Name View Source Status
0001558370-22-008441-index-headers.html Edgar Link pending
0001558370-22-008441-index.html Edgar Link pending
0001558370-22-008441.txt Edgar Link pending
0001558370-22-008441-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
xlo-20220331.xsd Edgar Link pending
xlo-20220331x10q.htm Edgar Link pending
xlo-20220331x10q_htm.xml Edgar Link completed
xlo-20220331xex10d1.htm Edgar Link pending
xlo-20220331xex31d1.htm Edgar Link pending
xlo-20220331xex31d2.htm Edgar Link pending
xlo-20220331xex32d1.htm Edgar Link pending
xlo-20220331_cal.xml Edgar Link unprocessable
xlo-20220331_def.xml Edgar Link unprocessable
xlo-20220331_lab.xml Edgar Link unprocessable
xlo-20220331_pre.xml Edgar Link unprocessable